正文共:3300字1图预计阅读时间:10分钟“这一数据证实了司美格鲁肽的独特性,它是目前唯一一款在肥胖且伴有心血管疾病、但无糖尿病的患者中,被证实具有心血管获益的GLP-1类药物。”——Ludovic Helfgott诺和诺德产品与产品组合战略执行副总裁心血管获益证据+12025年8月31日,诺和诺德公布了STEER真实世界研究的最新证据(RWE),为诺和盈®(境外商品名Wegovy®,司美格鲁肽...
Source Link正文共:3300字1图预计阅读时间:10分钟“这一数据证实了司美格鲁肽的独特性,它是目前唯一一款在肥胖且伴有心血管疾病、但无糖尿病的患者中,被证实具有心血管获益的GLP-1类药物。”——Ludovic Helfgott诺和诺德产品与产品组合战略执行副总裁心血管获益证据+12025年8月31日,诺和诺德公布了STEER真实世界研究的最新证据(RWE),为诺和盈®(境外商品名Wegovy®,司美格鲁肽...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.